Related Experiment Video

Updated: Jun 7, 2025

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

8.8K

EGFR-Targeted Therapies: A Literature Review

Calista Sha1, Paul C Lee1

  • 1Department of Cardiothoracic Surgery, Long Island Jewish Medical Center, New Hyde Park, NY 11040, USA.

Journal of Clinical Medicine
|November 9, 2024
PubMed

Insights

Lung cancer treatment is improving with targeted therapies. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) offer a more selective approach for non-small-cell lung cancer (NSCLC).

Area of Science:

  • Oncology
  • Molecular Genomics
  • Pharmacology

Background:

  • Lung cancer is a leading cause of cancer mortality in the US.
  • Conventional treatments have limitations.
  • Targeted therapy offers improved selectivity and reduced side effects.

Purpose of the Study:

  • To conduct a comprehensive literature review on EGFR TKIs.
  • To explore advancements in molecular genomics for lung cancer.
  • To contribute to optimizing lung cancer treatment strategies.

Main Methods:

  • Systematic literature review.
  • Analysis of current research on EGFR TKIs.
  • Synthesis of findings related to molecular genomics and targeted therapy.

Main Results:

  • EGFR TKIs are a key component of targeted therapy for NSCLC.
  • Significant progress has been made in understanding EGFR mutations.
  • TKIs demonstrate efficacy in specific patient populations.

Conclusions:

  • EGFR TKIs represent a significant advancement in lung cancer treatment.
  • Further research is needed to refine personalized treatment approaches.
  • Integration of molecular genomics is crucial for future therapeutic development.
Keywords:
EGFRNSCLCTKIlung cancer

More Related Videos

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

7.9K
Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation15:05

Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation

Published on: May 20, 2020

8.5K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.6K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.7K